Ketamine in the Treatment of Depression
DOI:
https://doi.org/10.12775/JEHS.2025.78.57672Keywords
ketamine, depression, antidepressant, psychiatryAbstract
Introduction
Depression is one of the most common mental illnesses. Over the course of a lifetime, several percent of the adult population suffers from depression. There are many treatments for depression like pharmacotherapy and psychotherapy. In this article, we wanted to focus on the effectiveness of ketamine in treating depression.
Aim of study
The study aimed to summarize the available knowledge on the use of ketamine in the treatment of depression. The epidemiology, etiology, side effects, and treatment methods, were summarized and described.
Materials and method
The literature available in the PubMed database was reviewed using the following keywords: “Ketamine”,” Depression”, and “Antidepressants”.
Conclusion
Without a doubt, ketamine has proven to be a new advocate for mental health research and therapeutics. After over half a century without novel targets for MDD (Major Depressive Disorder) treatment, the observation of ketamine’s rapid antidepressant effects in treatment-resistant depression has become a promising field that could represent a breakthrough in the understanding of MDD, and the possibility of reducing some of the major personal and global burden that depression is responsible for. It seems imminent then that a new era of different acting antidepressant strategies is upon us, and it is our responsibility to make a critical analysis of the potential benefits and harm inherent to novel therapeutics.
References
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137-150. https://doi.org/10.1016/S2215-0366(21)00395-3
Castro A, Gili M, Visser M, et al. Soft Drinks and Symptoms of Depression and Anxiety in Overweight Subjects: A Longitudinal Analysis of an European Cohort. Nutrients. 2023;15(18):3865. Published 2023 Sep 5. https://doi.org/10.3390/nu1518386
Jakobsen JC, Gluud C, Kirsch I. Should antidepressants be used for major depressive disorder?. BMJ Evid Based Med. 2020;25(4):130. https://doi.org/10.1136/bmjebm-2019-111238
Dean RL, Hurducas C, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021;9(9):CD011612. Published 2021 Sep 12. https://doi.org/10.1002/14651858.CD011612.pub3
Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians?. World Psychiatry. 2010;9(3):155-161. https://doi.org/10.1002/j.2051-5545.2010.tb00298.x
Coppen A. The biochemistry of affective disorders. Br J Psychiatry. 1967;113(504):1237-1264. https://doi.org/10.1192/bjp.113.504.1237
Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864.https://doi.org/10.1001/archpsyc.63.8.856
Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405. https://doi.org/10.1001/jamapsychiatry.2017.0080
Zhdanava M, Pilon D, Ghelerter I, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699. Published 2021 Mar 16. https://doi.org/10.4088/JCP.20m13699
Contreras-Osorio F, Ramirez-Campillo R, Cerda-Vega E, et al. Effects of Physical Exercise on Executive Function in Adults with Depression: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022;19(22):15270. Published 2022 Nov 18.https://doi.org/10.3390/ijerph192215270
Scott F, Hampsey E, Gnanapragasam S, et al. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. J Psychopharmacol. 2023;37(3):268-278. https://doi.org/10.1177/02698811221104058
Runia N, Yücel DE, Lok A, et al. The neurobiology of treatment-resistant depression: A systematic review of neuroimaging studies. Neurosci Biobehav Rev. 2022;132:433-448. https://doi.org/10.1016/j.neubiorev.2021.12.008
Pérez-Esparza R. Ketamine for Treatment-Resistant Depression: a New Advocate. Rev Invest Clin. 2018;70(2):65-67. https://doi.org/10.24875/RIC.18002501
Li L, Vlisides PE. Ketamine: 50 Years of Modulating the Mind. Front Hum Neurosci. 2016;10:612. Published 2016 Nov 29. doi:10.3389/fnhum.2016.006 1https://doi.org/10.3389/fnhum.2016.00612
Veraart JKE, Smith-Apeldoorn SY, Spijker J, Kamphuis J, Schoevers RA. Ketamine Treatment for Depression in Patients With a History of Psychosis or Current Psychotic Symptoms: A Systematic Review. J Clin Psychiatry. 2021;82(4):20r13459. Published 2021 Jul 13. https://doi.org/10.4088/JCP.20r13459
Tully JL, Dahlén AD, Haggarty CJ, Schiöth HB, Brooks S. Ketamine treatment for refractory anxiety: A systematic review. Br J Clin Pharmacol. 2022;88(10):4412-4426. https://doi.org/10.1111/bcp.15374
Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 1997;86(4):903-917. https://doi.org/10.1097/00000542-199704000-00021
Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry. 2012;169(11):1150-1156. https://doi.org/10.1176/appi.ajp.2012.12040531
Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349-352. https://doi.org/10.1016/j.biopsych.2007.05.028
Alnefeesi Y, Chen-Li D, Krane E, et al. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. J Psychiatr Res. 2022;151:693-709. https://doi.org/10.1016/j.jpsychires.2022.04.037
Ng J, Rosenblat JD, Lui LMW, et al. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. J Affect Disord. 2021;293:285-294. https://doi.org/10.1016/j.jad.2021.06.032
Kwaśny A, Włodarczyk A, Ogonowski D, Cubała WJ. Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review. Pharmaceuticals (Basel). 2023;16(4):568. Published 2023 Apr 10. https://doi.org/10.3390/ph16040568
Conley AA, Norwood AEQ, Hatvany TC, Griffith JD, Barber KE. Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis. Psychopharmacology (Berl). 2021;238(7):1737-1752. https://doi.org/10.1007/s00213-021-05825-8
Shamabadi A, Ahmadzade A, Aqamolaei A, Mortazavi SH, Hasanzadeh A, Akhondzadeh S. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials. Iran J Psychiatry. 2022;17(3):320-340. ttps://doi.org/10.18502/ijps.v17i3.9733
Rodolico A, Cutrufelli P, Di Francesco A, et al. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis. Front Psychiatry. 2024;15:1325399. Published 2024 Feb 1. https://doi.org/10.3389/fpsyt.2024.1325399
Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis [published correction appears in J Affect Disord. 2021 Feb 15;281:1001. doi: 10.1016/j.jad.2020.11.103]. J Affect Disord. 2021;278:542-555. https://doi.org/10.1016/j.jad.2020.09.071
Singh JB, Daly EJ, Mathews M, et al. Approval of esketamine for treatment-resistant depression. Lancet Psychiatry. 2020;7(3):232-235. https://doi.org/10.1016/S2215-0366(19)30533-4
Martinotti G, Dell'Osso B, Di Lorenzo G, et al. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar Disord. 2023;25(3):233-244. https://doi.org/10.1111/bdi.13296
Kasper S, Cubała WJ, Fagiolini A, Ramos-Quiroga JA, Souery D, Young AH. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. World J Biol Psychiatry. 2021;22(6):468-482. https://doi.org/10.1080/15622975.2020.1836399
Arabzadeh S, Hakkikazazi E, Shahmansouri N, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J Affect Disord. 2018;235:236-241. https://doi.org/10.1016/j.jad.2018.02.056
Grott Zanicotti C, Perez D, Glue P. Case report: long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med. 2013;16(7):719-720. https://doi.org/10.1089/jpm.2013.0057
Cavenaghi VB, da Costa LP, Lacerda ALT, Hirata ES, Miguel EC, Fraguas R. Subcutaneous Ketamine in Depression: A Systematic Review. Front Psychiatry. 2021;12:513068. Published 2021 May 28. https://doi.org/10.3389/fpsyt.2021.513068
Bonnet U. Long-Term Ketamine Self-Injections in Major Depressive Disorder: Focus on Tolerance in Ketamine's Antidepressant Response and the Development of Ketamine Addiction. J Psychoactive Drugs. 2015;47(4):276-285. https://doi.org/10.1080/02791072.2015.1072653
Chen CC, Zhou N, Hu N, Feng JG, Wang XB. Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis. Neuropsychiatr Dis Treat. 2023;19:587-599. Published 2023 Mar 14. https://doi.org/10.2147/NDT.S401032
Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials [published correction appears in Aust N Z J Psychiatry. 2020 Jul;54(7):766. doi: 10.1177/0004867420928878]. Aust N Z J Psychiatry. 2020;54(1):29-45. https://doi.org/10.1177/0004867419883341
Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. https://doi.org/10.1016/s0006-3223(99)00230-9
McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021;178(5):383-399. https://doi.org/10.1176/appi.ajp.2020.20081251
Papakostas GI, Salloum NC, Hock RS, et al. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry. 2020;81(4):19r12889. Published 2020 May 26. https://doi.org/10.4088/JCP.19r12889
Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(9):893-903. https://doi.org/10.1001/jamapsychiatry.2019.1189
Kritzer MD, Pae CU, Masand PS. Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Expert Opin Drug Saf. 2022;21(6):725-732. https://doi.org/10.1080/14740338.2022.2069749
Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250-256. https://doi.org/10.1016/j.biopsych.2012.06.022
Rodrigues NB, McIntyre RS, Lipsitz O, et al. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence [published correction appears in Expert Opin Drug Saf. 2020 Aug;19(8):i.Expert Opin Drug Saf. 2020;19(8):1031-1040. https://doi.org/10.1080/14740338.2020.1776699
DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605-1611. https://doi.org/10.4088/JCP.09m05327blu
McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021;178(5):383-399. https://doi.org/10.1176/appi.ajp.2020.20081251
Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65-78. https://doi.org/10.1016/S2215-0366(17)30272-9
Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247-252. https://doi.org/10.4088/JCP.13m08852
Pérez-Esparza R, Kobayashi-Romero LF, García-Mendoza AM, Lamas-Aguilar RM, Fonseca-Perezamador A. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression. Acta Psychiatr Scand. 2019;140(2):182-183. https://doi.org/10.1111/acps.13063
Mayberg TS, Lam AM, Matta BF, Domino KB, Winn HR. Ketamine does not increase cerebral blood flow velocity or intracranial pressure during isoflurane/nitrous oxide anesthesia in patients undergoing craniotomy. Anesth Analg. 1995;81(1):84-89. https://doi.org/10.1097/00000539-199507000-00017
Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247-252. https://doi.org/10.4088/JCP.13m08852
Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142.https://doi.org/10.1176/appi.ajp.2013.13030392
Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study [published correction appears in Addiction. 2010 Apr;105(4):766]. Addiction. 2010;105(1):121-133. https://doi.org/10.1111/j.1360-0443.2009.02761.x
Wu P, Wang Q, Huang Z, Wang J, Wu Q, Lin T. Clinical staging of ketamine-associated urinary dysfunction: a strategy for assessment and treatment. World J Urol. 2016;34(9):1329-1336. https://doi.org/10.1007/s00345-016-1759-9
Cohen SP, Bhatia A, Buvanendran A, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521-546.https://doi.org/10.1097/AAP.0000000000000808
Beck K, Hindley G, Borgan F, et al. Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(5):e204693. Published 2020 May 1.https://doi.org/10.1001/jamanetworkopen.2020.4693
Liu Y, Lin D, Wu B, Zhou W. Ketamine abuse potential and use disorder. Brain Res Bull. 2016;126(Pt 1):68-73. https://doi.org/10.1016/j.brainresbull.2016.05.016
Botanas CJ, de la Peña JB, Dela Peña IJ, et al. Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: Evidence of its abuse potential. Pharmacol Biochem Behav. 2015;133:31-36. https://doi.org/10.1016/j.pbb.2015.03.007
Bokor G, Anderson PD. Ketamine: an update on its abuse. J Pharm Pract. 2014;27(6):582-586. https://doi.org/10.1177/0897190014525754
Morgan CJ, Curran HV; Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 2012;107(1):27-38. https://doi.org/10.1111/j.1360-0443.2011.03576.x
Powers AR 3rd, Gancsos MG, Finn ES, Morgan PT, Corlett PR. Ketamine-Induced Hallucinations. Psychopathology. 2015;48(6):376-385. https://doi.org/10.1159/000438675
Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522-526. https://doi.org/10.1016/j.biopsych.2009.04.029
Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry. 2018;175(4):327-335. https://doi.org/10.1176/appi.ajp.2017.17060647
Vande Voort JL, Ballard ED, Luckenbaugh DA, et al. Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. J Clin Psychiatry. 2017;78(8):1068-1074. https://doi.org/10.4088/JCP.15m10440
Deisenhammer EA, Ing CM, Strauss R, Kemmler G, Hinterhuber H, Weiss EM. The duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt?. J Clin Psychiatry. 2009;70(1):19-24.
Claassen CA, Trivedi MH, Rush AJ, et al. Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. J Affect Disord. 2007;97(1-3):77-84. https://doi.org/10.1016/j.jad.2006.05.026
Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, et al. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial [published correction appears in BMC Psychiatry. 2020 Jan 8;20(1):9. doi: 10.1186/s12888-019-2398-7]. BMC Psychiatry. 2019;19(1):375. Published 2019 Nov 29. https://doi.org/10.1186/s12888-019-2359-1
Psiuk D, Nowak EM, Dycha N, Łopuszańska U, Kurzepa J, Samardakiewicz M. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. Int J Mol Sci. 2022;23(19):11450. Published 2022 Sep 28. https://doi.org/10.3390/ijms231911450
Meshkat S, Rosenblat JD, Ho RC, et al. Ketamine use in pediatric depression: A systematic review. Psychiatry Res. 2022;317:114911. https://doi.org/10.1016/j.psychres.2022.114911
Guo J, Qiu D, Gu HW, et al. Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies. Mol Psychiatry. 2023;28(6):2266-2276. https://doi.org/10.1038/s41380-023-01945-z
Banov MD, Young JR, Dunn T, Szabo ST. Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. CNS Spectr. 2020;25(3):331-342. https://doi.org/10.1017/S1092852919001238
Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351. https://doi.org/10.1176/appi.ajp.2007.06111868
Sanacora, G., & Schatzberg, A. F. (2015). Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(2), 259–267..https://doi.org/10.1038/npp.2014.261
Drozdz SJ, Goel A, McGarr MW, et al. Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. J Pain Res. 2022;15:1691-1706. Published 2022 Jun 15. https://doi.org/10.2147/JPR.S360733
Keizer BM, Roache JD, Jones JR, Kalpinski RJ, Porcerelli JH, Krystal JH. Continuous Ketamine Infusion for Pain as an Opportunity for Psychotherapy for PTSD: A Case Series of Ketamine-Enhanced Psychotherapy for PTSD and Pain (KEP-P2). Psychother Psychosom. 2020;89(5):326-329. https://doi.org/10.1159/000507095
Ocker AC, Shah NB, Schwenk ES, Witkowski TA, Cohen MJ, Viscusi ER. Ketamine and Cognitive Behavioral Therapy for Rapid Opioid Tapering With Sustained Opioid Abstinence: A Case Report and 1-Year Follow-up. Pain Pract. 2020;20(1):95-100. https://doi.org/10.1111/papr.12829
Dore J, Turnipseed B, Dwyer S, et al. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs. 2019;51(2):189-198. https://doi.org/10.1080/02791072.2019.1587556
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Urszula Agnieszka Kaczmarska, Michał Jakub Cioch, Julia Nowak, Aleksandra Woźniak, Kamil Hermanowicz, Agnieszka Najdek , Daria Oleksy , Dawid Komada, Katarzyna Doman , Marcin Mycyk

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 124
Number of citations: 0